Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2009

View Archived Issues

Omeprazole immediate-release exhibits favorable pharmacokinetics in GERD patients with gastroparesis

Safety, pharmacokinetic results with ZYH-1 in healthy subjects reported

GPR119 agonist MBX-2982 shows potential in treating diabetes

Promising first-in-human results for CAM-3001 in rheumatoid arthritis

Update on phase III results for eplivanserin in insomnia

Clinical studies of ENB-0040 in hypophosphatasia patients reported

11beta-HSD1 inhibition may benefit cognition

Novel ORL-1 antagonist with a favorable preclinical profile enters clinical trials as an analgesic

ActoGeniX receives FDA approval to initiate phase Ib clinical trials of AG-013 in cancer

FDA accepts for standard review IntelGenx's NDA for antidepressant CPI-300

Javelin completes safety study of Dyloject in the U.S. in acute postoperative pain

PharmaSwiss submits NDA in Israel for BioSante's Elestrin

Nippon Boehringer Ingelheim and Astellas launch Micombi for hypertension in Japan

GSK and Chroma to develop macrophage-targeted drugs using Chroma's ESM technology

Takeda completes tender offer for all outstanding shares of IDM Pharma common stock

Cytopia files IND with FDA for JAK2 inhibitor CYT-387

National Jewish Health reports results from preclinical animal testing of Ceragenix's CSA-13

Biovista presents efficacy results in a preclinical trial of BVA-601

Compugen reports therapeutic effects of novel peptide in animal model of IBS

Kyowa Hakko Kirin initiates phase II study for KW-0761 in T-cell lymphoma

Resolvyx initiates phase I RX-10001 trial for asthma and inflammatory diseases

Restanza shows 100% survival in confirmatory nonhuman primate anthrax study

Silence Therapeutics doses first patient in ATU-027 trial for solid tumors

Novel HIV-1 Nef protein ligands claimed by INSERM and CNRS for the treatment of AIDS

deCODE describes PDE4 inhibitors in development for the treatment of stroke

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...